GoAI
Get started
Medpace Holdings, Inc. logo

Medpace Holdings, Inc.

MEDP

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Latest quote

$620.93

+$8.11 · +1.32%

Aug 21, 3:55 PM ET

MEDP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

51

Neutral

Sentiment

59

Mixed

Risk resilience

65

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
August James Troendle
Listed since
Aug 11, 2016
Employees
6,500

Market position

Volume
225.88K
0.63× average
Average volume
357.43K
Average daily volume
Market cap
17.33B USD
Beta
1.15
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
35.7×
P/B (TTM)
40.5×
P/S (TTM)
6.23×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
28.76%
Operating margin
20.97%
Net margin
17.67%

Financial health

Debt / equity
0.28×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends33%26%20%13%Gross margin, FY2021: 28.73%Gross margin, FY2022: 29.62%Gross margin, FY2023: 27.81%Gross margin, FY2024: 31.12%Gross margin, FY2025: 30.06%Operating margin, FY2021: 17.39%Operating margin, FY2022: 19.09%Operating margin, FY2023: 17.86%Operating margin, FY2024: 21.19%Operating margin, FY2025: 21.14%Net margin, FY2021: 15.92%Net margin, FY2022: 16.81%Net margin, FY2023: 15.00%Net margin, FY2024: 19.17%Net margin, FY2025: 17.83%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 28.73%. Gross margin FY2022 29.62%. Gross margin FY2023 27.81%. Gross margin FY2024 31.12%. Gross margin FY2025 30.06%. Operating margin FY2021 17.39%. Operating margin FY2022 19.09%. Operating margin FY2023 17.86%. Operating margin FY2024 21.19%. Operating margin FY2025 21.14%. Net margin FY2021 15.92%. Net margin FY2022 16.81%. Net margin FY2023 15.00%. Net margin FY2024 19.17%. Net margin FY2025 17.83%.

Income trends

Revenue

2.53B USD+19.97%

Operating income

534.94M USD+19.71%

Net income

451.12M USD+11.56%
Income trends across reported periods2.77B USD1.83B USD886.36M USD−52.99M USDRevenue, FY2021: 1.14B USDRevenue, FY2022: 1.46B USDRevenue, FY2023: 1.89B USDRevenue, FY2024: 2.11B USDRevenue, FY2025: 2.53B USDOperating income, FY2021: 198.62M USDOperating income, FY2022: 278.7M USDOperating income, FY2023: 336.83M USDOperating income, FY2024: 446.87M USDOperating income, FY2025: 534.94M USDNet income, FY2021: 181.85M USDNet income, FY2022: 245.37M USDNet income, FY2023: 282.81M USDNet income, FY2024: 404.39M USDNet income, FY2025: 451.12M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.14B USD. Revenue FY2022 1.46B USD. Revenue FY2023 1.89B USD. Revenue FY2024 2.11B USD. Revenue FY2025 2.53B USD. Operating income FY2021 198.62M USD. Operating income FY2022 278.7M USD. Operating income FY2023 336.83M USD. Operating income FY2024 446.87M USD. Operating income FY2025 534.94M USD. Net income FY2021 181.85M USD. Net income FY2022 245.37M USD. Net income FY2023 282.81M USD. Net income FY2024 404.39M USD. Net income FY2025 451.12M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.53B USD2.11B USD1.89B USD1.46B USD1.14B USD
Cost of goods sold1.77B USD1.45B USD1.36B USD1.03B USD814.22M USD
Gross profit760.62M USD656.31M USD524.51M USD432.44M USD328.16M USD
Selling, general, and administrative197.56M USD180.18M USD161.35M USD131.4M USD108.42M USD
Operating expenses225.68M USD209.44M USD187.68M USD153.74M USD129.54M USD
Interest income—25M USD———
Interest expense——488K USD2.91M USD105K USD
Depreciation and amortization28.12M USD29.25M USD26.33M USD22.34M USD21.12M USD
Operating income534.94M USD446.87M USD336.83M USD278.7M USD198.62M USD
Net income451.12M USD404.39M USD282.81M USD245.37M USD181.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+12.88%
11 comparable reports
Latest EPS result
4.25
Estimate 3.98 · Beat by 6.78%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.864.163.472.77Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 3.67, estimate 2.96, surprise +23.99%, Beat. Q2 2025, reported Apr 21, 2025: actual 3.67, estimate 3.06, surprise +19.93%, Beat. Q3 2025, reported Jul 21, 2025: actual 3.1, estimate 2.98, surprise +4.03%, Beat. Q4 2025, reported Oct 22, 2025: actual 3.86, estimate 3.53, surprise +9.35%, Beat. Q1 2026, reported Feb 9, 2026: actual 4.67, estimate 4.19, surprise +11.46%, Beat. Q2 2026, reported Apr 22, 2026: actual 4.28, estimate 3.92, surprise +9.18%, Beat. Q3 2026, reported Jul 22, 2026: actual 4.25, estimate 3.98, surprise +6.78%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 4.39, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates742.84M661.15M579.46M497.77MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 536.59M USD, estimate 539.74M USD, surprise -0.58%, Miss. Q2 2025, reported Apr 21, 2025: actual 558.57M USD, estimate 526.34M USD, surprise +6.12%, Beat. Q3 2025, reported Jul 21, 2025: actual 603.31M USD, estimate 538.77M USD, surprise +11.98%, Beat. Q4 2025, reported Oct 22, 2025: actual 659.9M USD, estimate 641M USD, surprise +2.95%, Beat. Q1 2026, reported Feb 9, 2026: actual 708.45M USD, estimate 689.31M USD, surprise +2.78%, Beat. Q2 2026, reported Apr 22, 2026: actual 706.6M USD, estimate 697.6M USD, surprise +1.29%, Beat. Q3 2026, reported Jul 22, 2026: actual 707.33M USD, estimate 689.51M USD, surprise +2.58%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 714.27M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

19 ratings
Strong buy00%
Buy421%
Hold1474%
Sell15%
Strong sell00%

MEDP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MEDP

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
466.05M
Weight
0.36%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
419.67M
Weight
0.02%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
303.08M
Weight
0.16%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Invesco S&P MidCap Quality ETF logoInvesco S&P MidCap Quality ETFXMHQ
Market value
181.69M
Weight
3.22%
AUM
5.67B USD
Expense ratio
0.31%
Price / 1D
$119.27+0.45%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
175.39M
Weight
0.39%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
150.04M
Weight
0.16%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
105.39M
Weight
0.99%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
State Street SPDR S&P MIDCAP 400 ETF Trust logoState Street SPDR S&P MIDCAP 400 ETF TrustMDY
Market value
101.23M
Weight
0.38%
AUM
26.72B USD
Expense ratio
0.23%
Price / 1D
$699.6+0.48%

Continue in GoAI

Research MEDP

research.disclaimer